Introduction {#S0001}
============

In December 2019, a series of pneumonia cases of unknown etiology emerged in Wuhan, Central China with a population of 11 million people and was thought to be related to an exposure from Huanan Seafood Wholesale Market \[[1](#CIT0001),[2](#CIT0002)\]. This condition was later confirmed to be the coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Different from normal pathogens, this virus is powerful and has extended rapidly to other Chinese cities and countries, thus leading to the widespread of pneumonia \[[3](#CIT0003)--[5](#CIT0005)\]. The number of COVID-19 cases has sharply increased in China and by 13 times outside China, and the number of affected countries tripled. Consideration its alarming levels of spread and severity, the World Health Organization characterized COVID-19 as a pandemic on March 11, 2020. COVID-19 poses a great public health and clinical burden worldwide.

The epidemiological and clinical characteristics of patients with COVID-19 have been reported. SARS-CoV-2 infection has a wide clinical spectrum, including asymptomatic infection, mild respiratory disease, and severe pneumonia with acute respiratory failure and even death. Hematological changes, including lymphopenia and thrombocytopenia, have been reported in patients with COVID-19 similar to SARS in 2003 \[[6](#CIT0006),[7](#CIT0007)\]. Abnormal coagulation is a common complication of COVID-19 and is manifested by pulmonary vascular leakage, intravascular thrombosis, and disseminated intravascular coagulation. Thrombocytopenia is also a common clinical manifestation associated with poor outcome in patients with community-acquired pneumonia \[[8](#CIT0008)\]. Platelets not only contribute to hemostasis, but also participate in inflammation and host defense response. The latter is especially important when the lungs are infected. Although many cases of thrombocytopenia have been reported in patients with severe viral pneumonia and thus is a suggestive clinical characteristic of COVID-19, the association of baseline platelets and changes with adverse COVID-19 outcome remains unclear.

Here, a hospital-based cohort study was conducted in all patients with laboratory-confirmed COVID-19 to evaluate the association between platelets at admission and mortality, particularly the dynamic changes of circulating platelets and its role in the disease progression.

Methods {#S0002}
=======

Participants {#S0002-S2001}
------------

A retrospective cohort study was conducted on 383 patients with COVID-19 in the Central Hospital of Wuhan from January 2, 2020 and followed to March 1, 2020. COVID-19 was diagnosed according to the World Health Organization interim guidance \[[9](#CIT0009)\]. Only patients with laboratory-confirmed human infection from throat swab specimens were enrolled, and those with malignant tumors, post craniocerebral operation, died on admission, treatment with anti-platelet drugs, and transferred to other medical institutions were excluded. All enrolled patients were followed up until discharge or death. The requirement for informed consent was waived due to the urgency to collect data on the emerging SARS-CoV-2. This study was approved by the Ethics Committees of the Central Hospital of Wuhan.

Data Collection {#S0003}
===============

Case report forms, nursing records, laboratory findings, and radiological characteristics were reviewed by a team of physicians who treat patients with COVID-19. Demographic characteristics (gender and age), comorbidities (chronic obstructive pulmonary disease, hypertension, diabetes, cardiovascular disease, cerebrovascular disease, and chronic kidney disease), clinical manifestations, laboratory findings, treatment, and outcomes (discharge/death) were extracted from electronic medical records. Laboratory data, including white blood cell count, neutrophil count, lymphocyte count, hemoglobin, platelet count, C-reactive protein, procalcitonin, blood urea nitrogen, creatinine, total bilirubin, alanine aminotransferase, aspartate aminotransferase, fibrinogen, D-dimer, lactate dehydrogenase, creatine kinase, and arterial blood gases (lactate and PaO~2~/FiO~2~ ratio), were collected at admission. Additional platelet parameters, including plateletcrit (PCT, %), mean platelet volume (MPV, fL), platelet distribution width (%), and platelet larger cell ratio (*P*-LCR, %) were also gathered. According to the test projectmanual and reagent instructions of the Central Hospital of Wuhan, the normal reference interval of platelet count was 125--350 × 10^9^/L. Therefore, thrombocytopenia was defined as a blood platelet \<125 × 10^9^/L, and non-thrombocytopenia was defined as a blood platelet $>$125 × 10^9^/L. Acute Physiology and Chronic Health Evaluation II scores (APACHE II), sequential organ failure assessment, and CURB-65 criteria were determined within 24 h after admission. Data on all treatment measures, including antibiotic, antivirus, glucocorticoid, and intravenous immunoglobulin therapy and respiratory support, were acquired during hospitalization. Throat swab samples were collected from all suspected patients at admission, and the laboratory confirmation of SARS-CoV-2 was performed using real-time reverse transcription-polymerase chain reaction according to the manufacturer's protocol (Beijing Genomics Institution and Geneodx biotechnology Co., Ltd.). Repeated tests for SARS-CoV-2 were performed in confirmed patients to verify viral clearance before hospital discharge.

Statistical analysis {#S0004}
====================

Baseline characteristics as continuous and categorical variables were presented as median (interquartile range) and *n* (%), respectively, and examined by Mann--Whitney U test, χ^2^ test, or Fisher's exact test where appropriate. The association between baseline platelet parameters and mortality risk was estimated by Cox proportional hazards regression models in terms of the following confounders: age, sex, baseline comorbidities (including chronic obstructive pulmonary disease, hypertension, diabetes, chronic kidney disease, cardiovascular disease, and cerebrovascular disease). Glucocorticoid and immunoglobulin might affect the hematopoietic system, and these treatments are common in clinical practice. In addition, decreased lymphocyte count represents the progression of the disease, C-reactive protein represents the overall inflammation, and augment blood lactate represents acute lung injury, tissue hypoxia and/or oxygen debt and associated mortality critical patients \[[10](#CIT0010)\]. Therefore, we also considered these in regression models. Smoothing spline presenting the association of baseline platelet levels and platelets change with subsequent mortality was generated by utilizing the generalized additive model. Survival curve was plotted using the Kaplan--Meier method and examined using the log-rank test. All statistical analyses were performed using R software (The R Foundation, <http://www.r-project.org>, version 3.6.1) and EmpowerStats (<http://www.empowerstats.com>, X&Y Solutions, Inc., Boston, MA) unless otherwise indicated. A two-sided significance level of *P* = 0.05 was used to evaluate statistical significance.

Results {#S0005}
=======

Patients characteristics {#S0005-S2001}
------------------------

Among the 383 COVID-19 patients with median 18 days (range 4 to 50 days) follow-up period, 334 (87.2%) were discharged and survived, and 49 (12.8%) died. The clinical characteristics of all patients stratified by admission platelets are presented in [Table I](#T0001). The median age was 46 years, and 162 (42.3%) patients were male. No significant differences in comorbidities were observed between patients with thrombocytopenia and non-thrombocytopenia. Patients with thrombocytopenia at admission were likely older and had a higher APACHE II score than those with non-thrombocytopenia. Most patients were administered with antibiotics, and some were treated with ribavirin (88.3%), oseltamivir (25.6%), and arbidol (20.9%). Empiric systemic glucocorticoid therapy (58.2%) and intravenous immunoglobulin (56.1%) were used for anti-inflammatory treatment. Noninvasive ventilation was used on 51 patients (13.3%). The thrombocytopenia group had a higher proportion of noninvasive ventilation therapy (26.5% vs. 10.5%) and mortality rate (30.9% vs. 8.9%) than those without thrombocytopenia. The dynamic changes in platelet count from day 1 to day 14 after the onset of the disease were tracked to determine the major clinical features observed during COVID-19 progression. Compared with that for non-survivors, the level of platelets showed an increasing trend for survivors after admission (*P* \< 0.05, [Figure 1](#F0001)). Additionally, platelets were negatively associated with APACHE II score, higher of which indicates the higher disease severity at admission ([Figure 2](#F0002)).10.1080/09537104.2020.1754383-T0001Table I.Baseline characteristics of COVID-19 patients with thrombocytopenia and without thrombocytopenia. Total (*n* = 383)Thrombocytopenia (*n* = 68)Non-thrombocytopenia (*n* = 315)*P*-value^a^**Age, median (IQR), y**46 (34--61)52 (38--65)43 (33--60)**0.004Male**162 (42.3%)38 (55.9%)124 (39.4%)**0.01Comorbidities**     COPD17 (4.4%)6 (8.8%)11 (3.5%)0.09 Hypertension81 (21.1%)18 (26.5%)63 (20.0%)0.24 Diabetes36 (9.4%)8 (11.8%)28 (8.9%)0.49 Cardiovascular disease14 (3.7%)2 (2.9%)12 (3.8%)\>0.99 Cerebrovascular disease14 (3.7%)3 (4.4%)11 (3.5%)0.72 Chronic kidney disease19 (5.0%)6 (8.8%)13 (4.1%)0.12**Baseline severity of illness**     CURB65   **0.005** 1273 (71.3%)39 (57.4%)234 (74.3%)  $>$1110 (28.7%)29 (42.6%)81 (25.7%)  APACHEII, median (IQR)2 (1--4)4 (2--8)2 (0--4)**\<0.001Laboratory findings, median (IQR)**     White blood cell count, ×10^9^/L4.8 (3.6--6.3)3.9 (2.7--5.1)5.0 (3.8--6.5)**\<0.001** Neutrophil count, ×10^9^/L3.2 (2.0--4.5)2.8 (1.5--3.8)3.3 (2.2--4.7)**0.005** Lymphocyte count, ×10^9^/L1.0 (0.7--1.4)0.8 (0.5--1.1)1.1 (0.8--1.5)**\<0.001** Hemoglobin, g/L131 (122--141)131 (120--141)131 (122--141)0.80 Procalcitonin, ng/mL0.05 (0.04--0.08)0.06 (0.05--0.17)0.05 (0.04--0.07)**\<0.001** C-reactive protein, mg/dL1.2 (0.3--3.9)2.5 (0.8--4.5)1.0 (0.2--3.6)**0.002** Total bilirubin, mmol/L8 (6--12)9 (7--13)8 (6--11)**0.023** Alanine aminotransferase, U/L19 (13--30)24 (14--31)18 (13--30)0.12 Aspartate aminotransferase, U/L21 (17--33)29 (20--41)21 (17--30)**\<0.001** Blood urea nitrogen, mmol/L4.0 (3.2--5.2)4.6 (3.5--6.0)4.0 (3.2--4.9)**0.004** Creatinine, μmol/L64 (52--78)69 (59--83)63 (50--76)**0.006** Fibrinogen, g/L2.9 (2.4--3.4)2.9 (2.5--3.2)2.8 (2.4--3.5)0.75 D-dimer, mg/L0.4 (0.2--0.8)0.5 (0.3--1.0)0.4 (0.2--0.8)**0.033** Lactate, mmol/L1.2 (0.8--1.6)1.2 (0.8--1.8)1.2 (0.7--1.6)0.19 PaO~2~:FIO~2~, mm Hg420 (270--528)337 (208--520)424 (280--540)**0.008Platelet parameters, median (IQR)**     Platelet count, ×10^9^/L174 (137--213)105 (92--116)186 (160--227)**\<0.001** Plateletcrit, %0.18 (0.14--0.22)0.11 (0.09--0.12)0.19 (0.16--0.23)**\<0.001** The mean platelet volume, fL10.0 (9.2--10.7)10.3 (9.6--10.9)9.9 (9.1--10.6)**0.001** The platelet distribution width, %15.5 (10.9--16.4)12.9 (11.0--16.5)15.8 (10.9--16.3)0.81 The platelet larger cell ratio, %25.2 (20.1--31.1)28.5 (22.6--33.7)24.3 (19.8--30.2)**0.003Treatment**     Quinolones254 (66.3%)42 (61.8%)212 (67.3%)0.38 Cephalosporins191 (49.9%)41 (60.3%)150 (47.6%)0.06 Ribavirin338 (88.3%)60 (88.2%)278 (88.3%)\>0.99 Oseltamivir98 (25.6%)17 (25.0%)81 (25.7%)0.90 Arbidol80 (20.9%)12 (17.6%)68 (21.6%)0.45 Glucocorticoid therapy223 (58.2%)45 (66.2%)178 (56.5%)0.14 Intravenous immunoglobulin215 (56.1%)39 (57.4%)176 (55.9%)0.82 noninvasive ventilation51 (13.3%)18 (26.5%)33 (10.5%)**0.001Clinical outcomes**   **\<0.001** Hospital discharge334 (87.2%)47 (69.1%)287 (91.1%)  Death49 (12.8%)21 (30.9%)28 (8.9%) [^2][^3] 10.1080/09537104.2020.1754383-F0001Figure 1.Timeline charts illustrate the platelet levels in 383 patients with COVID-19 (49 non-survivors and 334 survivors) on day 1, day 3, day 7, and day 14 after admissionData are represented as median and 95% confidence interval. The dash lines in black show the upper normal limit of platelets, and the dash line in red shows the lower normal limit of platelets. Generalized linear-mixed models examined the differences in the platelets between non-survivor and survivor groups over time.\* *P* \< .05 for non-survivor *vs*. survivor.10.1080/09537104.2020.1754383-F0002Figure 2.The smoothing spline presenting the association between baseline platelet count and APACHE II score was generated by utilizing the generalized additive model.

Laboratory findings {#S0006}
===================

At admission, patients with thrombocytopenia had lower white blood cell, neutrophil, and lymphocyte count and higher levels of procalcitonin and C-reactive protein compared with those without thrombocytopenia ([Table I](#T0001)). Remarkable differences were found in the levels of total bilirubin, aspartate aminotransferase, blood urea nitrogen, creatinine, and D-dimer. These indicators were significantly higher in patients with thrombocytopenia than in those without thrombocytopenia. Decreased levels of PaO~2~:FIO~2~ were observed in the thrombocytopenia group compared with those in the non-thrombocytopenia group. Analysis of platelet parameters revealed that patients with thrombocytopenia had lower levels of platelets and PCT and higher levels of MPV and *P*-LCR than those without thrombocytopenia.

Association between platelets and mortality {#S0007}
===========================================

Cox proportional hazard regression models adjusted for several death-related risk factors at admission, including age, sex, baseline comorbidities, lymphocyte count, blood lactate, C-reactive protein, glucocorticoid therapy, and intravenous immunoglobulin. The results revealed that after adjustment for potential confounders, platelets and PCT were independent risks for mortality ([Table II](#T0002)). In dose--response analyses, per 50 × 10^9^/L increment in platelet count were significantly associated with 40% decreased mortality (HR 0.60, 95%CI: 0.43, 0.84) in all patients ([Table III](#T0003)). In the analysis of 261 patients with a platelet count below 200 × 10^9^/L, the association was still robust. A smoothing spline was further plotted to visually present the non-linear relationship between platelets at admission and mortality. We observed the mortality decreased with elevating platelet count, and the curve gradually tends to be gentle when platelet count \>200 × 10^9^/L ([Figure 3a](#F0003)). Continuous tracking of the changes in platelets within the first 7 days after admission revealed that when platelets increased, the risk of death decreased during the treatment and vice-versa ([Figure 3b](#F0003)). Further analysis showed that the worst outcome was noted in the subgroup of patients with a platelet level \<200 × 10^9^/L at admission and decrease in 7 days, followed by patients with a platelet level \<200 × 10^9^/L at admission and increase in 7 days, patients with a platelet level $>$200 × 10^9^/L at admission and decrease in 7 days, and patients with a platelet level $>$200 × 10^9^/L at admission and increase in 7 days ([Figure 4](#F0004)).10.1080/09537104.2020.1754383-T0002Table II.Association between platelet parameters and subsequent mortality estimated by Cox proportional hazards regression models. Quartile 1Quartile 2Quartile 3Quartile 4*P* trend**Platelet levels, ×10^9^/L**\<138138-174174-213$>$213  No. of death/total25/9610/9410/954/98  Crude model5.42 (1.89, 15.60)2.20 (0.69, 7.02)2.29 (0.72, 7.31)1.00 (ref.)\<0.001 Model 13.86 (1.27, 11.79)2.88 (0.86, 9.67)2.77 (0.84, 9.10)1.00 (ref.)0.02 Model 24.24 (1.32, 13.61)3.74 (1.06, 13.18)3.72 (1.10, 12.53)1.00 (ref.)0.03**Plateletcrit, %**\<0.140.14--0.180.18--0.22$>$0.22  No. of death/total23/8612/10310/914/103  Crude model6.24 (2.16, 18.04)2.51 (0.81, 7.79)2.46 (0.77, 7.84)1.00 (ref.)\<0.001 Model 14.82 (1.59, 14.57)2.49 (0.76, 8.17)2.51 (0.77, 8.17)1.00 (ref.)0.003 Model 26.46 (2.03, 20.56)2.64 (0.76, 9.11)3.00 (0.90, 10.05)1.00 (ref.)0.001**The mean platelet volume, fL**\<9.29.2--10.010.0--10.7$>$10.7  No. of death/total8/8710/10111/9320/102  Crude model0.54 (0.24, 1.23)0.57 (0.27, 1.21)0.56 (0.27, 1.18)1.00 (ref.)0.11 Model 10.84 (0.36, 1.96)0.53 (0.24, 1.18)0.66 (0.30, 1.44)1.00 (ref.)0.35 Model 20.67 (0.27, 1.65)0.49 (0.22, 1.12)0.46 (0.19, 1.09)1.00 (ref.)0.22**The platelet distribution width, %**\<11.011.0--15.515.5--16.4$>$16.4  No. of death/total11/9616/959/9313/99  Crude model0.87 (0.39, 1.95)1.13 (0.55, 2.36)0.84 (0.36, 1.97)1.00 (ref.)0.94 Model 11.40 (0.61, 3.23)2.04 (0.93, 4.50)1.07 (0.44, 2.62)1.00 (ref.)0.19 Model 21.46 (0.62, 3.45)2.78 (1.19, 6.45)0.94 (0.37, 2.42)1.00 (ref.)0.12**The platelet larger cell ratio, %**\<2020-2525-31$>$31  No. of death/total7/9411/9612/9619/97  Crude model0.41 (0.17, 0.97)0.67 (0.32, 1.41)0.58 (0.28, 1.20)1.00 (ref.)0.06 Model 10.74 (0.30, 1.82)0.74 (0.34, 1.62)0.62 (0.29, 1.30)1.00 (ref.)0.45 Model 20.69 (0.27, 1.78)0.90 (0.39, 2.08)0.48 (0.20, 1.14)1.00 (ref.)0.58[^4][^5][^6][^7][^8] 10.1080/09537104.2020.1754383-T0003Table III.Association between the increase of platelet per 50 × 10^9^/L and mortality risk. Increase per 50 × 10^9^/L over the whole range of platelet count*P* valueIncrease per 50 × 10^9^/L when\
platelets below 200 × 10^9^/L*P* valueNo. of death/total49/383 44/261 Crude model0.51 (0.38, 0.69)\<0.0010.50 (0.33, 0.76)0.001Model 10.63 (0.46, 0.85)0.0030.62 (0.40, 0.95)0.03Model 20.60 (0.43, 0.84)0.0030.62 (0.39, 0.98)0.04[^9][^10][^11] 10.1080/09537104.2020.1754383-F0003Figure 3.The nonlinear relationship of (a) platelets at admission and (b) platelet changes with mortality.The smoothing splines were generated utilizing generalized additive model and adjusted for age, sex, baseline comorbidities (including chronic obstructive pulmonary disease, hypertension, diabetes, chronic kidney disease, cardiovascular disease, and cerebrovascular disease), glucocorticoid therapy, intravenous immunoglobulin, blood lactate, C-reactive protein, and lymphocyte count. The red line indicates the risk of mortality and the blue dot line indicates 95% confidence intervals.10.1080/09537104.2020.1754383-F0004Figure 4.Kaplan--Meier curves stratified by platelet count at admission and platelet changes in 7 days.

Discussion {#S0008}
==========

Patients with COVID-19 usually have a rapid progression of pneumonitis and even develop ARDS and death. Among the 383 COVID-19 patients enrolled, most were admitted with platelets in the normal range, and a few had thrombocytopenia. Although the majority of current studies revealed a decreased number of platelets in groups with severe COVID-19 \[[6](#CIT0006),[7](#CIT0007)\], no research has investigated the dynamic changes of platelets and estimated the association of baseline platelets and platelets change with subsequent mortality in patients infected with SARS-CoV-2. In the present study, clinical characteristics were compared between patients with and without thrombocytopenia. Cox proportional hazard regression analysis was used to adjust for several death-related risk factors at admission. Our study highlights the following: (a) thrombocytopenia at admission was associated with mortality that is almost three times higher than that in patients without thrombocytopenia; (b) platelet count was an independent risk factor for COVID-19 mortality; and (c) the dynamic changes of platelets were closely related to death during treatment. Our study highlights that platelet monitoring might be important for COVID-19 prognosis.

Enhanced platelet activation leading to platelet deposition in damaged pulmonary blood vessels has been supported by various clinical studies, and thrombocytopenia is an important feature of SARS \[[11](#CIT0011),[12](#CIT0012)\]. Thrombocytopenia has exceeded 50% incidence rate in patients with SARS and is an important indicator of poor prognosis \[[13](#CIT0013)--[15](#CIT0015)\]. A meta-analysis with 1779 COVID-19 patients reported that thrombocytopenia was associated with threefold-enhanced risk of severe COVID-19 and an lower platelet count was observed with mortality \[[16](#CIT0016)\]. Similar to this study, the current work confirmed that thrombocytopenia at admission is associated with death in patients with COVID-19. Platelets in patients with SARS are negatively correlated with their sVCAM-1 levels. sVCAM-1 is involved in adhesion and chemotaxis and contributes to early vascular injury and suppression of T cell function. Vascular injury or immunosuppression may explain the poor outcome \[[17](#CIT0017)\]. By using the Cox regression model for multivariate analysis, we found that platelets and PCT are independent risk factors that predict death. Although platelets were routinely measured daily, the role of platelets and PCT in predicting the outcome of patients with COVID-19 has not been previously reported, and the correlation between platelet dynamics and disease prognosis has not been studied. Different platelet thresholds have been used in epidemiological studies for the incidence, risk factors, and consequences of thrombocytopenia among critically ill patients \[[18](#CIT0018),[19](#CIT0019)\]. In our cohort, a non-linear relationship between platelets at admission and mortality was observed, and the trend tends to be gentle when platelet count \>200 × 10^9^/L ([Figure 3a](#F0003)). Further analysis showed that patients with a platelet level \<200 × 10^9^/L at admission and decrease in 7 days had the highest mortality rate, whereas those with a platelet level $>$200 × 10^9^/L at admission and increase in 7 days had the lowest mortality rate. Moreover, thrombocytopenia had a close relationship with prognosis even within the normal reference range. The dynamic changes of platelets within the first 7 days after admission were negatively correlated with the prognosis. Cox proportional hazards regression models displayed a 40% decrease in mortality risk for every 50 × 10^9^/L increase in platelets. In summary, platelet count is an important prognostic marker for patients with COVID-19, and the dynamic levels of platelets during treatment are closely associated with death. PCT was calculated from platelet count, and its levels at admission still retained a detrimental effect on clinical outcome \[[20](#CIT0020)\].

The mechanism of SARS-CoV-2 on thrombocytopenia is poorly understood, but several potential explanations are considered \[[21](#CIT0021)\]. Histological examinations of lung necropsy from patients with COVID-19 revealed bilateral diffuse alveolar damage with cellular fibromyxoid exudates and interstitial mononuclear inflammatory infiltrates as dominated by lymphocytes; this finding has raised the possibility of immunopathological damage for lung tissues \[[22](#CIT0022)\]. Damaged lung tissues would cause platelet activation and aggregation in the lungs, and thrombi formation at the site of the injury may lead to the consumption of platelets and megakaryocytes. In addition, SARS-CoV-2 induces a low-grade disseminated intravascular coagulopathy state characterized by the elevation of D-dimers and fibrinogen and further increases the consumption of platelets in damaged lungs. The lungs may be the sites of platelet release from mature megakaryocytes \[[23](#CIT0023)\]. Inflammation and long-term oxygen treatment also result in extensive alveolar damage and other pulmonary pathological changes. The pulmonary capillary bed is morphologically altered, thus further affecting the lung megakaryocyte fragmentation and megakaryocytopoiesis. The increased consumption and decreased production of platelet may affect thrombocytopenia. Similar to SARS coronavirus, SARS-CoV-2 thrombocytopenia may involve other mechanisms. This new condition may directly infect hematopoietic precursor cells and inhibit their growth. CD 13 and CD66a are expressed on human bone marrow CD34+ cells. SARS-CoV-2 may induce growth inhibition by binding to the CD13 or CD66a of hematopoietic cells and bone marrow stromal cells, resulting in abnormal hematopoiesis and immunodeficiency \[[21](#CIT0021)\]. The body undergoes immune-mediated hematopoietic stem cell damage, thereby further leading to thrombocytopenia.

This study is subjected to several limitations. First, as an observational study, we cannot conclude that the reported associations between platelet parameters and mortality are causal. Second, we cannot exclude the possibility of remaining residual confounding or unmeasured potential confounders. Third, the pathological mechanism of platelet parameters in the progression of COVID-19 remains poorly defined, and further clinical and basic research are necessary to clarify this issue. Although this study is the first to identify the association between platelet parameters and mortality risk in patients with COVID-19, a large-scale and multi-center study is warranted to confirm these findings.

Conclusions {#S0009}
===========

This hospital-based cohort study among 383 confirmed patients with COVID-19 revealed an association of baseline platelets and platelets change with subsequent mortality. Hence, monitoring platelets during hospitalization may be important in the prognosis of patients with SARS-CoV-2.
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